Subscribe to RSS
DOI: 10.1055/s-0044-1786983
Identification of Population-Specific Novel Protein Biomarkers and Possible Therapeutic Targets in Gliomas by Proteomics Approach
Abstract
Objective To analyze the differential proteomic profile of gliomas in patients from South India and to identify novel protein glioma biomarkers and possible therapeutic targets to tailor the treatment to individual patients.
Material and Methods We have prospectively analyzed the differential proteomic profile of 34 patients with glioma imaging characteristics and compared them with that of normal brain tissue. This research was conducted at the Institute of Neurosurgery, Madras Medical College, in technical collaboration with the Indian Institute of Technology, Madras, over 1 year.
Statistical Analysis Biological variate analysis (I-ANALYSIS OF VARIANCE (ANOVA)) was used, with p-value less than 0.05 being significant.
Results Twenty proteins (10 upregulated and 10 downregulated) were differentially expressed in tumor tissue. The expression of three pro-apoptotic proteins was downregulated and the expression of three anti-apoptotic proteins was upregulated with statistical significance. The cellular functions of the 20 differentially regulated proteins were subjected to pathway analysis revealing significant alterations in heme biosynthesis, deoxyribonucleic acid (DNA) replication, fibroblast growth factor (FGF) signaling, and epidermal growth factor (EGF0 receptor signaling in glioma.
Conclusion KRT18, PRS4, and EF1A2 are anti-apoptotic proteins and are significantly upregulated in gliomas. EARS2, COX5A, and LSM3 are pro-apoptotic proteins, and are significantly downregulated in gliomas. This subverts the apoptotic pathways resulting in prolonged cell survival. This study's statistically significant dysregulation of these six proteins was unique, suggesting that they might be considered population-specific biomarkers and possible therapeutic targets for patients from South India. Abnormalities of heme biosynthesis at the proteomic level were identified in this study, which has not been very well studied previously.
Ethical Approval Statement
The approval was obtained from the Institutional ethics committee.
Publication History
Article published online:
17 May 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109 (01) 93-108
- 2 Nandakumar A, Ramnath T. Consolidated report of Hospital-based registries 2004–2006. National Cancer Registry Programme. Bangalore: Indian Council for Medical Research; 2009: 54
- 3 Somasundaram K, Nijaguna MB, Mohankumar D. Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 2009; 9 (07) 695-707
- 4 Cervi D, Yip TT, Bhattacharya N. et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008; 111 (03) 1201-1207
- 5 Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics 2010; 73 (10) 1823-1838
- 6 Furuta M, Weil RJ, Vortmeyer AO. et al. Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 2004; 23 (40) 6806-6814
- 7 Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM. Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res 2004; 10 (03) 981-987
- 8 Chumbalkar VC, Subhashini C, Dhople VM. et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005; 5 (04) 1167-1177
- 9 Park CK, Jung JH, Park SH, Jung HW, Cho BK. Multifarious proteomic signatures and regional heterogeneity in glioblastomas. J Neurooncol 2009; 94 (01) 31-39
- 10 Puchades M, Nilsson CL, Emmett MR. et al. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J Proteome Res 2007; 6 (02) 869-875
- 11 Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988; 60 (20) 2299-2301
- 12 Iwadate Y, Sakaida T, Hiwasa T. et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004; 64 (07) 2496-2501
- 13 Odreman F, Vindigni M, Gonzales ML. et al. Proteomic studies on low- and high-grade human brain astrocytomas. J Proteome Res 2005; 4 (03) 698-708
- 14 Hiratsuka M, Inoue T, Toda T. et al. Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun 2003; 309 (03) 558-566
- 15 Ngo TT, Peng T, Liang XJ. et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 2007; 99 (08) 639-652
- 16 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. eds. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007
- 17 Horne SD, Pollick SA, Heng HHQ. Evolutionary mechanism unifies the hallmarks of cancer. Int J Cancer 2015; 136 (09) 2012-2021